Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Salvador Martín‐Algarra et al.|The Lancet|2012Cited by 3k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseChristine H. Chung, Thomas A.E. Platts‐Mills, Beloo Mirakhur et al.|New England Journal of Medicine|2008Cited by 1.5k
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Journal of Clinical Oncology|2013Cited by 112
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazineJean‐Jacques Grob, Axel Hauschild, Mayur M. Amonkar et al.|Annals of Oncology|2014Cited by 55
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365Axel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|Unknown|2012Cited by 7